90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study

Benedikt M Schaarschmidt; Moritz Wildgruber; Roman Kloeckner; James Nie; Verena Steinle; Arthur J A T Braat; Fabian Lohoefer; Hyun S Kim; Harald Lahner; Manuel Weber; Jens Theysohn

doi:10.2967/jnumed.121.262561

90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study

Benedikt M Schaarschmidt, Moritz Wildgruber, Roman Kloeckner, James Nie, Verena Steinle, Arthur J A T Braat, Fabian Lohoefer, Hyun S Kim, Harald Lahner, Manuel Weber, Jens Theysohn

30 Zitate (Scopus)

Abstract

In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits for 90Y RE are scarce. Therefore, the purpose of this study was to analyze the use of 90Y RE in NEN patients with hepatic metastases in an international, multicenter retrospective analysis and assess the potential role of 90Y RE in a multimodal treatment concept. Methods: In total, 297 angiographic evaluations in NEN patients before 90Y RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and 90Y RE were analyzed. Tumor response was assessed using RECIST 1.1, and survival data were collected. Mean overall survival (OS) between different groups was compared using Kaplan-Meier curves and the log rank test. A P value of less than 0.05 indicated statistical significance. Results: After 90Y RE, the disease control rate according to RECIST 1.1 was 83.5% after 3 mo and 50.9% after 12 mo. OS in the entire population was 38.9 ± 33.0 mo. High tumor grade (P < 0.006) and high tumor burden (P = 0.001) were both associated with a significant decrease in OS. The presence of extrahepatic metastases (P = 0.335) and the type of metastatic vascularization pattern (P = 0.460) had no influence on OS. Patients who received 90Y RE as second-line therapy had a slightly longer but not statistically significant OS than patients who had 90Y RE in a salvage setting (44.8 vs. 30.6 mo, P = 0.078). Hepatic and global progression-free survival after 90Y RE was significantly decreased in heavily pretreated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respectively). Conclusion:90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.

Originalsprache	Englisch
Zeitschrift	Journal of Nuclear Medicine
Jahrgang	63
Ausgabenummer	5
Seiten (von - bis)	679-685
Seitenumfang	7
ISSN	0161-5505
DOIs	https://doi.org/10.2967/jnumed.121.262561 https://doi.org/10.2967/jnumed.121.262561
Publikationsstatus	Veröffentlicht - 05.2022

Fördermittel

Benedikt M. Schaarschmidt has received a research grant from PharmaCept. Moritz Wildgruber reports personal fees from Sirtex Medical, outside the submitted work, Roman Kloeckner reports personal fees from Boston Scientific, Bristol-Myers Squibb, Guerbet, SIRTEX, Roche, BTG, Ipsen, Siemens, and MSD-Merck Sharp & Dohme, outside the submitted work, Arthur Braat reports other fees from Terumo and Boston Scientific, outside the submitted work. Manuel Weber is on the speakers bureau for Boston Scientific. Jens Theysohn reports personal fees from BTG, outside the submitted work. No other potential conflict of interest relevant to this article was reported. Benedikt M. Schaarschmidt has received a research grant from PharmaCept. Moritz Wildgruber reports personal fees from Sirtex Medical, outside the submitted work, Roman Kloeckner reports personal fees from Boston Scientific, Bristol-Myers Squibb, Guer-bet, SIRTEX, Roche, BTG, Ipsen, Siemens, and MSD–Merck Sharp & Dohme, outside the submitted work, Arthur Braat reports other fees from Terumo and Boston Scientific, outside the submitted work. Manuel Weber is on the speakers bureau for Boston Scientific. Jens Theysohn reports personal fees from BTG, outside the submitted work. No other potential conflict of interest relevant to this article was reported.

Träger	Trägernummer
MSD-Merck
PharmaCept
Roche BioScience
BTG
Siemens CT
Ipsen

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen
SDG 9 – Industrie, Innovation und Infrastruktur

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Biomedizintechnik
Profilbereich: Lübeck Integrated Oncology Network (LION)

DFG-Fachsystematik

2.22-30 Radiologie
2.22-14 Hämatologie, Onkologie
2.22-33 Nuklearmedizin, Strahlentherapie, Strahlenbiologie

Dokumente

Weitere Links

Link to publication in Scopus

Zitieren

Schaarschmidt, B. M., Wildgruber, M., Kloeckner, R., Nie, J., Steinle, V., Braat, A. J. A. T., Lohoefer, F., Kim, H. S., Lahner, H., Weber, M., & Theysohn, J. (2022). 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study. Journal of Nuclear Medicine, 63(5), 679-685. https://doi.org/10.2967/jnumed.121.262561, https://doi.org/10.2967/jnumed.121.262561

@article{2655ddeb6b2249be87759b5b9efe89fc,

title = "90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study",

abstract = "In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits for 90Y RE are scarce. Therefore, the purpose of this study was to analyze the use of 90Y RE in NEN patients with hepatic metastases in an international, multicenter retrospective analysis and assess the potential role of 90Y RE in a multimodal treatment concept. Methods: In total, 297 angiographic evaluations in NEN patients before 90Y RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and 90Y RE were analyzed. Tumor response was assessed using RECIST 1.1, and survival data were collected. Mean overall survival (OS) between different groups was compared using Kaplan-Meier curves and the log rank test. A P value of less than 0.05 indicated statistical significance. Results: After 90Y RE, the disease control rate according to RECIST 1.1 was 83.5\% after 3 mo and 50.9\% after 12 mo. OS in the entire population was 38.9 ± 33.0 mo. High tumor grade (P < 0.006) and high tumor burden (P = 0.001) were both associated with a significant decrease in OS. The presence of extrahepatic metastases (P = 0.335) and the type of metastatic vascularization pattern (P = 0.460) had no influence on OS. Patients who received 90Y RE as second-line therapy had a slightly longer but not statistically significant OS than patients who had 90Y RE in a salvage setting (44.8 vs. 30.6 mo, P = 0.078). Hepatic and global progression-free survival after 90Y RE was significantly decreased in heavily pretreated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respectively). Conclusion:90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.",

author = "Schaarschmidt, \{Benedikt M\} and Moritz Wildgruber and Roman Kloeckner and James Nie and Verena Steinle and Braat, \{Arthur J A T\} and Fabian Lohoefer and Kim, \{Hyun S\} and Harald Lahner and Manuel Weber and Jens Theysohn",

note = "Publisher Copyright: {\textcopyright} 2022 by the Society of Nuclear Medicine and Molecular Imaging.",

year = "2022",

month = may,

doi = "10.2967/jnumed.121.262561",

language = "English",

volume = "63",

pages = "679--685",

journal = "Journal of Nuclear Medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

number = "5",

}

Schaarschmidt, BM, Wildgruber, M, Kloeckner, R, Nie, J, Steinle, V, Braat, AJAT, Lohoefer, F, Kim, HS, Lahner, H, Weber, M & Theysohn, J 2022, '90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study', Journal of Nuclear Medicine, Jg. 63, Nr. 5, S. 679-685. https://doi.org/10.2967/jnumed.121.262561, https://doi.org/10.2967/jnumed.121.262561

90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study. / Schaarschmidt, Benedikt M; Wildgruber, Moritz; Kloeckner, Roman et al.
in: Journal of Nuclear Medicine, Jahrgang 63, Nr. 5, 05.2022, S. 679-685.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - 90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms

T2 - Results of an International Multicenter Retrospective Study

AU - Schaarschmidt, Benedikt M

AU - Wildgruber, Moritz

AU - Kloeckner, Roman

AU - Nie, James

AU - Steinle, Verena

AU - Braat, Arthur J A T

AU - Lohoefer, Fabian

AU - Kim, Hyun S

AU - Lahner, Harald

AU - Weber, Manuel

AU - Theysohn, Jens

PY - 2022/5

Y1 - 2022/5

N2 - In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits for 90Y RE are scarce. Therefore, the purpose of this study was to analyze the use of 90Y RE in NEN patients with hepatic metastases in an international, multicenter retrospective analysis and assess the potential role of 90Y RE in a multimodal treatment concept. Methods: In total, 297 angiographic evaluations in NEN patients before 90Y RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and 90Y RE were analyzed. Tumor response was assessed using RECIST 1.1, and survival data were collected. Mean overall survival (OS) between different groups was compared using Kaplan-Meier curves and the log rank test. A P value of less than 0.05 indicated statistical significance. Results: After 90Y RE, the disease control rate according to RECIST 1.1 was 83.5% after 3 mo and 50.9% after 12 mo. OS in the entire population was 38.9 ± 33.0 mo. High tumor grade (P < 0.006) and high tumor burden (P = 0.001) were both associated with a significant decrease in OS. The presence of extrahepatic metastases (P = 0.335) and the type of metastatic vascularization pattern (P = 0.460) had no influence on OS. Patients who received 90Y RE as second-line therapy had a slightly longer but not statistically significant OS than patients who had 90Y RE in a salvage setting (44.8 vs. 30.6 mo, P = 0.078). Hepatic and global progression-free survival after 90Y RE was significantly decreased in heavily pretreated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respectively). Conclusion:90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.

AB - In neuroendocrine neoplasms (NENs), the presence of distant metastases has a severe impact on survival leading to a relevant decrease in the 5-y survival rate. Here, 90Y radioembolization (90Y RE) might be an important treatment option; however, data to support clinical benefits for 90Y RE are scarce. Therefore, the purpose of this study was to analyze the use of 90Y RE in NEN patients with hepatic metastases in an international, multicenter retrospective analysis and assess the potential role of 90Y RE in a multimodal treatment concept. Methods: In total, 297 angiographic evaluations in NEN patients before 90Y RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and 90Y RE were analyzed. Tumor response was assessed using RECIST 1.1, and survival data were collected. Mean overall survival (OS) between different groups was compared using Kaplan-Meier curves and the log rank test. A P value of less than 0.05 indicated statistical significance. Results: After 90Y RE, the disease control rate according to RECIST 1.1 was 83.5% after 3 mo and 50.9% after 12 mo. OS in the entire population was 38.9 ± 33.0 mo. High tumor grade (P < 0.006) and high tumor burden (P = 0.001) were both associated with a significant decrease in OS. The presence of extrahepatic metastases (P = 0.335) and the type of metastatic vascularization pattern (P = 0.460) had no influence on OS. Patients who received 90Y RE as second-line therapy had a slightly longer but not statistically significant OS than patients who had 90Y RE in a salvage setting (44.8 vs. 30.6 mo, P = 0.078). Hepatic and global progression-free survival after 90Y RE was significantly decreased in heavily pretreated patients, compared with patients with second-line therapy (P = 0.011 and P = 0.010, respectively). Conclusion:90Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.

UR - https://www.scopus.com/pages/publications/85125835426

U2 - 10.2967/jnumed.121.262561

DO - 10.2967/jnumed.121.262561

M3 - Journal articles

C2 - 34475236

AN - SCOPUS:85125835426

SN - 0161-5505

VL - 63

SP - 679

EP - 685

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

IS - 5

ER -

90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren